{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:01:09Z","timestamp":1793638869318,"version":"4.5.1"},"reference-count":16,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1507\/endocrj.ej17-0104","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T22:13:51Z","timestamp":1498601631000},"page":"819-826","source":"Crossref","is-referenced-by-count":33,"title":["Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma"],"prefix":"10.1507","volume":"64","author":[{"given":"Chie","family":"Masaki","sequence":"first","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminori","family":"Sugino","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Saitama Medical University, International Medical Center, Hidaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Ogimi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuyo","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadatoshi","family":"Osaku","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Akaishi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi Y.","family":"Hames","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Tomoda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Matsuzu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Uruno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ohkuwa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuji","family":"Nagahama","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takami","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","unstructured":"1. Klein Hesselink EN, Steenvoorden D, Kapiteijn E, Corssmit EP, van der Horst-Schrivers AN, <i>et al<\/i>. (2015) Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. <i>Eur J Endocrinol<\/i> 172: R215-225."},{"key":"2","unstructured":"2. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, <i>et al<\/i>. (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet<\/i> 384: 319-328."},{"key":"3","unstructured":"3. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, <i>et al<\/i>. (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. <i>J Thyroid Res<\/i> 2014: 638747."},{"key":"4","unstructured":"4. Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, <i>et al<\/i>. (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. <i>Vasc Cell<\/i> 6: 18."},{"key":"5","unstructured":"5. Okamoto K, Ikemori-Kawada M, Jestel A, von Konig K, Funahashi Y, <i>et al<\/i>. (2015) Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. <i>ACS Med Chem Lett<\/i> 6: 89-94."},{"key":"6","unstructured":"6. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, <i>et al<\/i>. (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. <i>N Engl J Med<\/i> 372: 621-630."},{"key":"7","unstructured":"7. Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, <i>et al<\/i>. (2016) Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. <i>J Clin Endocrinol Metab<\/i> 101: 4103-4109."},{"key":"8","unstructured":"8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, <i>et al<\/i>. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). <i>Eur J Cancer<\/i> 45: 228-247."},{"key":"9","unstructured":"9. Hui EP, Ma BB, King AD, Mo F, Chan SL, <i>et al<\/i>. (2011) Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. <i>Ann Oncol<\/i> 22: 1280-1287."},{"key":"10","unstructured":"10. Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, <i>et al<\/i>. (2013) Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. <i>J Clin Oncol<\/i> 31: 3764-3775."},{"key":"11","unstructured":"11. Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M, <i>et al<\/i>. (2015) Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). <i>Eur J Cancer<\/i> 51: 1927-1936."},{"key":"12","unstructured":"12. Miyake H, Miyazaki A, Imai S, Harada K, Fujisawa M (2016) Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan. <i>Target Oncol<\/i> 11: 175-182."},{"key":"13","unstructured":"13. Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, <i>et al<\/i>. (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. <i>Cancer Sci<\/i> 106: 1714-1721."},{"key":"14","unstructured":"14. Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, <i>et al<\/i>. (2017) Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. <i>Eur J Cancer<\/i> 75: 213-221."},{"key":"15","unstructured":"15. Werner RA, Luckerath K, Schmid JS, Higuchi T, Kreissl MC, <i>et al<\/i>. (2016) Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience. <i>Sci Rep<\/i> 6: 28081."},{"key":"16","unstructured":"16. Ito Y, Suzuki S, Ito K, Imai T, Okamoto T, <i>et al<\/i>. (2016) Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review]. <i>Endocr J<\/i> 63: 597-602."}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/8\/64_EJ17-0104\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T06:02:32Z","timestamp":1504332152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/8\/64_EJ17-0104\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej17-0104","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}